Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real‐World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study
Nephrology · 2025
DOI: 10.1111/nep.70140 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nephrology, 2025. Verfasst von Shuma Hirashio und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan. Hauptthemen laut MEDLINE: Darbepoetin alfa, Proteinuria, Hematinics, Renal Insufficiency, Chronic. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
Erythropoiesis‐stimulating agents (ESAs) may be associated with inhibition of urinary protein; however, information from large‐scale real‐world clinical settings is insufficient. We aimed to investigate whether darbepoetin alfa (DA) was associated with reduced proteinuria in patients with chronic kidney disease (CKD) using data from the ‘oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis‐stimulating agents, darbepoetiN alfa (BRIGHTEN)’ observational study.
Methods
In total, 1161 patients treated with DA were analysed, including 307 with diabetic kidney disease (DKD), 286 with nephrosclerosis and 285 with chronic glomerulonephritis. We estimated the nonlinear relationship between DA dose and change in urinary protein‐creatinine ratio (UPCR) at 12 weeks using a spline curve. We also explored the potential clinical relevance of the association between higher DA doses and changes in proteinuria by comparing the slope of DA dosage and UPCR reduction between patients with high and low ESA resistance, which is associated with CKD prognosis.
Results
The UPCR appeared to decrease as the DA dose exceeded 50 μg, particularly in the DKD group. The slopes of DA dosage and UPCR reduction significantly differed ( p = 0.009) between the high‐ and low‐ESA resistance groups, especially in patients with DKD ( p < 0.001). This difference was maintained after adjustment for factors such as the presence or absence of renin‐angiotensin‐aldosterone system inhibitors and blood pressure variability during the study period.
Conclusion
DA administration was associated with reduced proteinuria in a dose‐dependent manner, particularly in patients with DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan.
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
- Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation, Kobe, Japan.
- Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
ORCID-Profile: Shuma Hirashio, Takao Masaki
Zitieren
APA
Hirashio, S., Masaki, T., Kagimura, T., & Narita, I. (2025). Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real‐World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study. Nephrology. https://doi.org/10.1111/nep.70140
Vancouver
Hirashio S, Masaki T, Kagimura T, Narita I. Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real‐World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study. Nephrology. 2025. doi:10.1111/nep.70140
BibTeX
@article{Hirashio2025,
author = {Hirashio, Shuma and Masaki, Takao and Kagimura, Tatsuo and Narita, Ichiei},
title = {Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real‐World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study},
journal = {Nephrology},
year = {2025},
doi = {10.1111/nep.70140}
}
EUVIMED